Copyright
©The Author(s) 2025.
World J Gastrointest Pharmacol Ther. Jun 5, 2025; 16(2): 101268
Published online Jun 5, 2025. doi: 10.4292/wjgpt.v16.i2.101268
Published online Jun 5, 2025. doi: 10.4292/wjgpt.v16.i2.101268
Table 1 Demographic and clinical features of the study population, n (%)/mean ± SD
Total sample (n = 61) | Active treatment (n = 40) | Placebo (n = 21) | P value | |
Age | 42 ± 12 | 40 ± 11 | 45 ± 13 | 0.12 |
Gender | ||||
Female | 43 (70.5) | 28 (70.0) | 15 (71.4) | 1.00 |
Male | 18 (29.5) | 12 (30.0) | 6 (28.6) | |
Diagnosis | ||||
CD | 44 (72.1) | 31 (77.5) | 13 (61.9) | 0.24 |
UC | 17 (27.9) | 9 (22.5) | 8 (38.1) | |
Disease duration | 13 ± 10 | 10 ± 7 | 18 ± 12 | < 0.01 |
Previous resection | 16 (26.2) | 8 (20.0) | 8 (38.1) | 0.14 |
Biologic use | 40 (65.6) | 28 (70.0) | 12 (57.1) | 0.39 |
IBS severity | ||||
IBS-SSS at baseline | 285 ± 115 | 272 ± 129 | 308 ± 77 | 0.25 |
Mild | 9 (14.8) | 6 (15) | 3 (14) | 0.11 (severe vs mild-moderate) |
Moderate | 26 (42.6) | 20 (50.0) | 6 (28.6) | |
Severe | 26 (42.6) | 14 (35.0) | 12 (57.1) |
Table 2 Inflammatory bowel disease -related outcomes, n (%)
Total sample (n = 61) | Active agent (n = 40) | Placebo (n = 21) | P value | |
Biochemical flare | 8 (13.1) | 4 (10) | 4 (19.0) | 0.43 |
Steroid use or escalation of therapy | 8 (13.1) | 4 (10) | 4 (19.0) | 0.43 |
Biochemical flare or steroid or escalation of therapy | 10 (16.4) | 5 (12.5) | 5 (23.8) | 0.29 |
- Citation: Fennessy A, Doyle M, Boland A, Bourke R, O'Connor A. Four-strain probiotic exerts a positive effect on irritable bowel syndrome symptoms occurring in inflammatory bowel diseases in absence of inflammation (train-IBD trial). World J Gastrointest Pharmacol Ther 2025; 16(2): 101268
- URL: https://www.wjgnet.com/2150-5349/full/v16/i2/101268.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v16.i2.101268